{"name":"PharmaEssentia","slug":"pharmaessentia","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"PEG-Intron + Ribavirin","genericName":"PEG-Intron + Ribavirin","slug":"peg-intron-ribavirin","indication":"Chronic hepatitis C","status":"phase_3"},{"name":"P1101 + Ribavirin","genericName":"P1101 + Ribavirin","slug":"p1101-ribavirin","indication":"Chronic hepatitis C virus infection (genotype-dependent)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"KX01 ointment 1%","genericName":"KX01 ointment 1%","slug":"kx01-ointment-1","indication":"Other","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"P1101","genericName":"P1101","slug":"p1101","indication":"Immune thrombocytopenia (ITP)","status":"phase_3"}]}],"pipeline":[{"name":"PEG-Intron + Ribavirin","genericName":"PEG-Intron + Ribavirin","slug":"peg-intron-ribavirin","phase":"phase_3","mechanism":"PEG-Intron is a pegylated form of interferon-alpha, which is used to stimulate the body's immune response to fight viral infections, while Ribavirin is an antiviral medication that works by inhibiting viral replication.","indications":["Chronic hepatitis C","Chronic hepatitis B"],"catalyst":""},{"name":"KX01 ointment 1%","genericName":"KX01 ointment 1%","slug":"kx01-ointment-1","phase":"phase_3","mechanism":"KX01 is a topical ointment formulation designed to deliver therapeutic benefit through skin penetration for localized treatment.","indications":[],"catalyst":""},{"name":"P1101","genericName":"P1101","slug":"p1101","phase":"phase_3","mechanism":"P1101 is a recombinant human thrombopoietin (TPO) analog that stimulates platelet production by binding to the thrombopoietin receptor.","indications":["Immune thrombocytopenia (ITP)","Chemotherapy-induced thrombocytopenia"],"catalyst":""},{"name":"P1101 + Ribavirin","genericName":"P1101 + Ribavirin","slug":"p1101-ribavirin","phase":"phase_3","mechanism":"P1101 is an interferon lambda that enhances antiviral immunity, combined with ribavirin, a nucleoside analog that inhibits viral RNA synthesis.","indications":["Chronic hepatitis C virus infection (genotype-dependent)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxNVDlkaGVMU0pvejFWYjRKdEo5aDFQblc4bVFZaktSbWNfT25qOExsbndZVjgyMU82Nmx6VTVFb2N2RWI5VXo1Nk1JZ1Vwa3FrUVp2dU9IX1NlLXkwUm9xY0U5a3B5MnE2T0pySkNzMDdTa3pvQlRtemVXNmhSOTNKTmlHOHBuRDVmemk4UWkwbFNDUEdnVmd4NzJqd0RuVl80VUhBMFY0NHNtdHc3MndKeFNtS1pjWUV1eTMta05fRkQ2alRWOXc?oc=5","date":"2026-04-03","type":"pipeline","source":"BioSpace","summary":"PharmaEssentia Signs Investment Agreement for New Manufacturing Facility in Puerto Rico - BioSpace","headline":"PharmaEssentia Signs Investment Agreement for New Manufacturing Facility in Puerto Rico","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPTjNsRi0zd0U3RVNfT2JNUjJKaVpULV9sZGlFRGdHLWx2b1RQXzliWHp3N3hZdjNBTWJxdHRuU3ZpSEtGWlBaY2h1V3JsVkxmT2xUSHZ1MTluSE5fLW5mNFlQU2MwQXFnWmJLNU5BMWxwZVJMaU9yZi1sMkVucXVZWnNoaER1TU82c2VCYm1BN0dxdW0xQklxR1FEMkNUeUdjT2g4aEFSTW9oT0lfeG8tczZBaWtJZw?oc=5","date":"2026-04-02","type":"pipeline","source":"Contract Pharma","summary":"PharmaEssentia to Establish New Manufacturing Facility in Puerto Rico - Contract Pharma","headline":"PharmaEssentia to Establish New Manufacturing Facility in Puerto Rico","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNOWxocVQtZlo2azlNUnVjZlY3REZQMFVtNGVPdmlfUjBtc2VrcW9xakhtdkhveHVCa1AyTUFnMTdsRWRSUUhMcHdrZmpDMTlDaF9aemNSUUdEbE1Yblg4TUNvVE9KOUhOLXVsZXZWVU1nVk9LVW93em83RzRvWkRPamFERnN3eWdkVlE?oc=5","date":"2026-03-27","type":"pipeline","source":"News is My Business","summary":"PharmaEssentia formalizes $46M arrival to Puerto Rico - News is My Business","headline":"PharmaEssentia formalizes $46M arrival to Puerto Rico","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNYi1hUy1JbUlqTlp1LVgxU0tCcTVlNHo4MnFEenVlLW9Ec0htUFJQd3pFa0FieWNBVG83Zlp0RjlYTmZRaU04UjByWGgtcDNjeHNaLXEzQjJUREZZQXpoT25GblB5SkVWOGR4NG94bXlnSk16czlKOXI0cDY5bnVxWmF4aWRrLTRtaWhiWEQ1RWF6cWNHay10NFF6NUtmYUN2WWNxTTNIdmpLbjhadUdyaWZZNzlRWjFWM1l0cWJ1TVFpdk1obEhyMUZ3?oc=5","date":"2026-02-16","type":"pipeline","source":"BioSpectrum Asia","summary":"Taiwan's PharmaEssentia invests $46 M to build manufacturing plant in Puerto Rico - BioSpectrum Asia","headline":"Taiwan's PharmaEssentia invests $46 M to build manufacturing plant in Puerto Rico","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOam9fRFNSQm9xT2ZDSE5GeEZ2c0lDdWJ6SV9HRjA1Y1U5TWZIcmwwMnFEYXYtMWtsUzFIRFI3WXZidmZHb0g4MnRoeGlqMHAyUUh0SnE5YloyRjRkeXh1VjB1R1B5eExlblB6LU5OSnUyUk1ZX1RqdmZ5UUZ6b1NleHRTRTBhWU8tWkE?oc=5","date":"2026-02-13","type":"pipeline","source":"puerto rico report","summary":"More Pharma Manufacturing Investments in Puerto Rico - puerto rico report","headline":"More Pharma Manufacturing Investments in Puerto Rico","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNTm50Q1FfNFA1MzJaM1NnMUZhOHRwU05maHZoYXZGdEh6NU5kaVFiNjljVXo3dC1lQlBxR2p3TkdDMHlJVEYxbEJIbUhINmZqYjFWYTlQbmVfeWpMeFNxMTFKeGNvZW9DWDczNGIwSlF3T2hWYlFKaDlkS0dtcVdrZE9wcFlDLVZ1N3ZiZXRSdkRxeG55czU4eUdWZFFlOGlRN1lwaDdMWFg1SGJrVG5hNGw2eFlCS2daVHJwNnh3?oc=5","date":"2026-02-11","type":"pipeline","source":"BioProcess International","summary":"PharmaEssentia establishes US footprint with $46m Puerto Rican facility - BioProcess International","headline":"PharmaEssentia establishes US footprint with $46m Puerto Rican facility","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNbmQyTmNraHJyU1lJbEE4ME51VXZNRkduN1hMTEVzTEt4UjBZb1hkSUdNajM2LTdpNTVnblNTekVRazB0MHNNRGhyTF80SF80d2VqNXVxQXlDZ3NMNjU2RnhMV0dHMUdveThZcUo1bWxfWjdMR2E2bDhfQzQ1emsyX3VOVzhyX2pWSE5fQjdGRDBoWDFLSzFvc3p2OFIzZEswbXNwcE5LblR3YkU?oc=5","date":"2026-02-10","type":"pipeline","source":"Fierce Pharma","summary":"Taiwan’s PharmaEssentia to build $46M manufacturing plant in Puerto Rico - Fierce Pharma","headline":"Taiwan’s PharmaEssentia to build $46M manufacturing plant in Puerto Rico","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPR1diVEo1enVIWHRCcFRUZmFNQllhR2RCcXJrOWhpc002OHpianY3ckNqdnFCWmdlNEstVUJGOTFiNEVBWlowelpMT3dJNV9TY0I0UnRQMXV2a3pBV1hNVGdqMGkzVTFmV3hZU2NJQm5JZE16UGxRamJnLWs3Rldxcjd0R19UZ3N5MTNkNWV0SXdTX2lLXzJ3bHhxSlV2Sms?oc=5","date":"2026-02-09","type":"pipeline","source":"Business Facilities","summary":"PharmaEssentia Plans New U.S. Manufacturing Facility In Puerto Rico - Business Facilities","headline":"PharmaEssentia Plans New U.S. Manufacturing Facility In Puerto Rico","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxQdTBJekZ2WkVSUkRycVp2Q2hPMVhoTHg1ci1MOThmVnRhZWxMT3NPWE9BTUpYWjJVS2NxZk5KVC0xbEV1aXBUb0V3bHN6bzVHNFE3VU5NSTBWSDhpRmppTnF5b0RoWjh3ZFBZZFBiYUk4UFh2dzhsbHVrYUhVNHhHeXp0OEpWa183d2laUXg4ckVubFIySGtqWHZtc1MyWDNjV005ZVNwV1lvejdjdndrR0lLZVlZeENERzkyaDY4WXdWZXRZMWdkdXduZVZnLUhBcnB1eFU2dHVNR0ItYmxoZVhVVQ?oc=5","date":"2026-02-09","type":"pipeline","source":"PharmiWeb.com","summary":"PharmaEssentia Announces Plans to Establish New U.S. Manufacturing Facility in Puerto Rico to Suppor - PharmiWeb.com","headline":"PharmaEssentia Announces Plans to Establish New U.S. Manufacturing Facility in Puerto Rico to Suppor","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNQXY2ZFpPYTRaS1RWMUdKX3VLQ1VhV2F2TU1Mb3NYRU1Hd19BQkZqMEVHcV9aUDVxeW03dF8zTVdWNlk3c1UzRUtsb0ZfQVlUTGdVMnR0Q1hFN1h4cldYTVhtZGRsbWw1M194ai1wTTNRNEtwd2lNcDVWRlhicjJxQnlkS1lwZmo5MWRtYnM4SHR0UEt3SUN3?oc=5","date":"2026-01-27","type":"pipeline","source":"Yahoo Finance","summary":"PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for Treatment of Essential Thrombocythemia (ET) - Yahoo Finance","headline":"PharmaEssentia Announces Updated NCCN Clinical Practice Guidelines Include ropeginterferon alfa-2b-njft (BESREMi®) for T","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxNN3VUY2Q1UHBueF94ZTNEeXBWWFJ6RWZFQzg0NFpBVUJlRkppMk5KLXhTczczN3hNWld2UzRCRURlUDladEhscGxyS0ZnNnQtMkVvYWp5NUpFVWptbkd1ZGItT292V0pyODYxekJqLUNEcllNN0xLaTBRRVItamlCV0l1RkhMSE5tamtJbmJRQlNDRlhIQ0RkY0RXdWUxUERHTXpaSWZITjJoY2E1YjN0aQ?oc=5","date":"2026-01-13","type":"regulatory","source":"The Pharma Letter","summary":"PharmaEssentia’s sBLA in essential thrombocythemia accepted by FDA - The Pharma Letter","headline":"PharmaEssentia’s sBLA in essential thrombocythemia accepted by FDA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE5fOEhxdHVfdHhueFZURHRpamN6VGZUOVpLalVuQ0EwOVBiLUR2d0t6dnJPTm9CeUN0TTdaNVJMTWc4VkNBTzN5QWtMc2puU08yaWZR?oc=5","date":"2025-06-03","type":"trial","source":"FirstWord Pharma","summary":"ASCO25: PharmaEssentia's Besremi hits mark in late-stage thrombocythaemia study - FirstWord Pharma","headline":"ASCO25: PharmaEssentia's Besremi hits mark in late-stage thrombocythaemia study","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":4},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}